TITLE

Cell Therapy Treatment for Critical Limb Ischemia

AUTHOR(S)
Prather, William R.
PUB. DATE
November 2009
SOURCE
Drug Discovery & Development;Nov/Dec2009, Vol. 12 Issue 10, p40
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article discusses the treatment of the peripheral artery disease (PAD) critical limb ischemia (CLI) through cell therapy. It is stated that clinical trials are conducted by Pluristem Therapeutics Inc. in the U.S. and Europe to identify the effectiveness of adherent stromal cell (ASC) in treating CLI. It notes that the bioreactor expansion of ASC produced placental expanded (PLX) cells. It also mentions the blood flow improvement with the intramuscular administration of PLX-PAD.
ACCESSION #
46983762

 

Related Articles

  • PLURISTEM GETS INTERIM TOP-LINE RESULTS FROM PLX-PAD TRIALS.  // Worldwide Biotech;Jun2010, Vol. 22 Issue 6, p3 

    The article reports on the interim top-line results from the Phase I clinical trials of Pluristem Therapeutics Inc. in Haifa, Israel, in June 2010, which utilize the placenta-derived cell therapy product PLX-PAD for treating critical limb ischemia (CLI). The interim data showed that PLX-PAD is...

  • PLURISTEM GETS DSMB APPROVAL FOR PLX-PAD FINAL DOSE LEVEL.  // Biotech Business;Apr2010, Vol. 23 Issue 4, p6 

    The article announces the approval received by Pluristem Therapeutics Inc. of Haifa, Israel from the Safety Monitoring Board to advance to the highest and final dose level with its placenta-derived cell therapy (PLX-PAD) trial in Europe for the treatment of critical limb ischemia (CLI). Dr. Hans...

  • Pluristem's Placenta-Derived Cell Therapy Yields Strong Early Data. Boggs, Jennifer // BioWorld International;5/5/2010, Vol. 15 Issue 18, p5 

    The article deals with the preliminary Phase I data released by Pluristem Therapeutics Inc. for its placenta-derived cell therapy treatment PLX-PAD in critical limb ischemia in May 2010. Information on the Phase I trial results is presented. It discloses the company's negotiations for a Phase II...

  • Pluristem's Placenta-Derived Cell Therapy Yields Strong Early Data. Boggs, Jennifer // BioWorld Today;4/28/2010, Vol. 21 Issue 81, p1 

    This article reports on the plan of Pluristem Therapeutics Inc. to conduct Phase II testing with its placenta-derived cell therapy treatment PLX-PAD in critical limb ischemia. The Israeli company announced the plan after reporting positive results from two Phase I trials of the treatment,...

  • Pluristem's PLX-PAD Plans Boosted by $36M Offering. Boggs, Jennifer // BioWorld Today;1/28/2011, Vol. 22 Issue 19, p1 

    The article offers information on the public offering held by Pluristem Theraprutics Inc. to secure funding for its plans for a Phase II/III trial of placenta-derived cell therapy PLX-PAD for critical limb ischemia (CLI). The offering involved 11 million shares sold at 3.25 U.S. dollars each,...

  • German trial nears for Pluristem.  // Cardiovascular Devices & Drugs;Apr2009, Vol. 15 Issue 4, p22 

    The article reports on the preparations being made by Pluristem Therapeutics for the planned clinical trial for its placental-derived stem cell product candidate PLX-PAD in Germany. The clinical trail will include patients diagnosed with critical limb ischemia. Such preparations include a dry...

  • In 2020, Pluristem Therapeutics' PLX-PAD Will Earn Decision Resources' Proprietary Clinical Gold Standard Status for Treatment of Peripheral Arterial Disease.  // Biomedical Market Newsletter;3/28/2012, Vol. 21, p1 

    The article informs that the PLX-PAD developed by Pluristem Therapeutics is expected to earn the clinical gold standard status by Decision Resources Inc. in 2020 for the treatment of peripheral arterial disease. It mentions that the PLX-PAD and the ixmyelocel-T developed by Aastrom Biosciences...

  • Corrections & Clarifications.  // BioWorld Today;4/30/2010, Vol. 21 Issue 83, p2 

    A correction to the article on Pluristem Therapeutics Inc. which appeared in the April 28, 2010 issue is presented.

  • Placenta-Derived Cell Therapy Yields Strong Data.  // Bioworld Week;5/3/2010, Vol. 18 Issue 18, p3 

    The article discusses the phase II testing of placenta-derived cell therapy treatment PLX-PAD in vital limb ischemia as supported by Pluristem Therapeutics Inc.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics